Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $19.6 million.

  • Intellia Therapeutics' Share-based Compensation fell 5051.87% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year decrease of 3113.05%. This contributed to the annual value of $154.3 million for FY2024, which is 1508.62% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Share-based Compensation stood at $19.6 million, which was down 5051.87% from $22.0 million recorded in Q2 2025.
  • Intellia Therapeutics' Share-based Compensation's 5-year high stood at $40.9 million during Q2 2024, with a 5-year trough of $6.4 million in Q1 2021.
  • For the 5-year period, Intellia Therapeutics' Share-based Compensation averaged around $25.8 million, with its median value being $24.6 million (2022).
  • In the last 5 years, Intellia Therapeutics' Share-based Compensation soared by 18784.25% in 2022 and then crashed by 5051.87% in 2025.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Share-based Compensation stood at $14.6 million in 2021, then soared by 69.12% to $24.6 million in 2022, then soared by 42.3% to $35.0 million in 2023, then grew by 13.05% to $39.6 million in 2024, then tumbled by 50.52% to $19.6 million in 2025.
  • Its Share-based Compensation was $19.6 million in Q3 2025, compared to $22.0 million in Q2 2025 and $21.8 million in Q1 2025.